BACKGROUND: Scirrhous gastric cancer is biologically aggressive, and the prognosis is poor even with curative surgery. We compared outcomes with different therapies in order to identify prognostic factors. METHODS: Records for 83 patients, who were treated between 1991 and 2004, were evaluated for survival and stage, treatment, and clinicopathological factors. RESULTS: Cumulative 5-year overall survival was 10.2% for all 83 patients, including 27 (32.5%) patients with stage II/III disease and 56 (67.4%) with stage IV disease. The 5-year overall survival rate and median survival time for patients with stage II/III disease after curative surgery were 24.3% and 1150 days. For patients with stage IV disease, 2-year and 5-year survival rates after initial surgery were 13.7% and 0% and median survival was 250 days. In contrast, preoperative chemotherapy for advanced, unresectable disease produced 2-year and 3-year overall survival rates of 53.6% and 26.8% and medican survival was 910 days. CONCLUSION: Aggressive surgery alone does not seem to improve outcome, but preoperative chemotherapy might be beneficial and should be investigated further.
BACKGROUND: Scirrhous gastric cancer is biologically aggressive, and the prognosis is poor even with curative surgery. We compared outcomes with different therapies in order to identify prognostic factors. METHODS: Records for 83 patients, who were treated between 1991 and 2004, were evaluated for survival and stage, treatment, and clinicopathological factors. RESULTS: Cumulative 5-year overall survival was 10.2% for all 83 patients, including 27 (32.5%) patients with stage II/III disease and 56 (67.4%) with stage IV disease. The 5-year overall survival rate and median survival time for patients with stage II/III disease after curative surgery were 24.3% and 1150 days. For patients with stage IV disease, 2-year and 5-year survival rates after initial surgery were 13.7% and 0% and median survival was 250 days. In contrast, preoperative chemotherapy for advanced, unresectable disease produced 2-year and 3-year overall survival rates of 53.6% and 26.8% and medican survival was 910 days. CONCLUSION: Aggressive surgery alone does not seem to improve outcome, but preoperative chemotherapy might be beneficial and should be investigated further.
Authors: H Furukawa; M Hiratsuka; T Iwanaga; S Imaoka; O Ishikawa; T Kabuto; Y Sasaki; M Kameyama; H Ohigashi; S Nakamori; T Yasuda Journal: Ann Surg Oncol Date: 1997 Apr-May Impact factor: 5.344
Authors: S Kinugasa; S Abe; M Tachibana; H Yoshimura; N Monden; D K Dhar; N Nagasue; Y Harada; S Nagaoka Journal: J Surg Oncol Date: 1997-07 Impact factor: 3.454
Authors: W Koizumi; S Tanabe; K Saigenji; A Ohtsu; N Boku; F Nagashima; K Shirao; Y Matsumura; M Gotoh Journal: Br J Cancer Date: 2003-12-15 Impact factor: 7.640
Authors: Jung Im Kim; Young Hoon Kim; Kyoung Ho Lee; So Yeon Kim; Yoon Jin Lee; Young Soo Park; Nayoung Kim; Dong Ho Lee; Hyung Ho Kim; Do Joong Park; Hye Seung Lee Journal: Korean J Radiol Date: 2013-07-17 Impact factor: 3.500